Nxera Pharma Licenses Lucerastat for Fabry Disease
The oral therapy is in Phase 3 trials, with an expected regulatory filing projected for 2029.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies' investments in rare diseases effectively improve patient treatment options?
Nxera Pharma has exercised its option to license the oral therapy lucerastat from Idorsia for Japan and select Asia-Pacific markets. The investigational drug is currently in a global Phase 3 clinical research stage for the treatment of Fabry disease.
Why it matters
This agreement accelerates the regional development of a potential new oral therapy for Fabry disease, a rare condition currently reliant on standard enzyme replacement treatments. By securing rights to this late-stage asset, Nxera Pharma aims to expand its rare disease portfolio in the Asia-Pacific region.
Lucerastat is an investigational oral substrate reduction therapy currently being evaluated in a 74-patient global Phase 3 clinical study. This program measures its efficacy compared to standard-of-care enzyme replacement therapies.
The players
Nxera Pharma
A biopharmaceutical company focused on R&D for rare diseases and specialized therapies.
Idorsia
A Switzerland-based biopharmaceutical firm specializing in small molecule discovery and development.
The details
Lucerastat functions as a substrate reduction therapy—a treatment method that inhibits the production of specific molecules that the body cannot process. In patients with Fabry disease, a genetic disorder, this prevents the buildup of fatty substances inside cells. The drug is currently being tested in the FAB-KLEAR study, a pivotal clinical trial examining its performance against existing infusion-based enzyme replacements.
Timeline
July 2023: Idorsia granted the initial licensing option to Nxera Pharma.
October 28, 2026: Nxera Pharma officially exercised its option to license the therapy.
2029: Expected regulatory filing for lucerastat.
The Tech Race
This deal places Nxera Pharma directly into the late-stage development race for Fabry disease treatments. It complements the existing global FAB-KLEAR trial while specifically targeting regulatory approval within the Japanese and broader Asian markets.
The therapy is strictly research-stage and not yet available for patient use in any market. Patients and providers should monitor the 2029 target for regulatory filings, which marks the next major milestone for potential clinical access.
The takeaway
This licensing deal signals a commitment to bringing non-infusion alternatives to the Fabry disease treatment market. Stakeholders should track the 2029 regulatory filing date to determine if the therapy successfully moves from Phase 3 testing to market authorization.
Further reading
For broader trends in rare disease drug development, visit Biotech.
Live Poll
Do you trust that pharmaceutical companies' investments in rare diseases effectively improve patient treatment options?
